Moreover, emerging therapies such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid antagonists may offer dual renal and cardiac protection, though evidence in advanced CKD remains limited [25]. The gene discussed is SLC5A2; the disease is chronic kidney disease.